18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy
Open Access
- 17 July 2013
- journal article
- clinical trial
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (9), 1528-1534
- https://doi.org/10.2967/jnumed.112.116921
Abstract
The potential of 18F-FDG PET changes was evaluated for prediction of response to concomitant chemoradiotherapy in patients with locally advanced non–small cell lung cancer (NSCLC). Methods: For 28 patients, 18F-FDG PET was performed before treatment, at the end of the second week of treatment, and at 2 wk and 3 mo after the completion of treatment. Standardized uptake value (SUV), maximum SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained. Early metabolic changes were defined as fractional change (ΔTLG) when 18F-FDG PET at the end of the second week was compared with pretreatment 18F-FDG PET. In-treatment metabolic changes, as measured by serial 18F-FDG PET, were correlated with standard criteria of response evaluation of solid tumors by means of CT imaging (Response Evaluation Criteria In Solid Tumors 1.1). Parameters were analyzed for stratification in progression-free survival (PFS). Results: When compared with early metabolic nonresponders, a ΔTLG decrease of 38% or more was associated with a significantly longer PFS (1-y PFS 80% vs. 36%, P = 0.02). Pretreatment TLG was found to be a prognostic factor for PFS. Conclusion: The degree of change in TLG was predictive for response to concomitant chemoradiotherapy as early as the end of the second week into treatment for patients with locally advanced NSCLC. Pretreatment TLG was prognostic for PFS.Keywords
This publication has 31 references indexed in Scilit:
- Prognostic Value of Metabolic Tumor Burden from 18F-FDG PET in Surgical Patients with Non–small-cell Lung CancerAcademic Radiology, 2013
- Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancerEuropean Journal Of Cancer, 2012
- 18 F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation doseRadiation Oncology, 2012
- Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based studyRadiotherapy and Oncology, 2011
- Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009